Precision Cancer Therapy in Rare Cancers
Phase 2
Recruiting
- Conditions
- Rare Malignant Neoplasm
- Interventions
- Registration Number
- NCT06119789
- Lead Sponsor
- Oslo University Hospital
- Brief Summary
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.
In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
- Detailed Description
All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
- ECOG 0-2,
- identified biomarker,
- reasonable biochemistry
Exclusion Criteria
- ECOG 3-5
- serious other diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description treatment according to genetic alterations Imatinib treatment according to genetic alterations treatment according to genetic alterations Trametinib treatment according to genetic alterations treatment according to genetic alterations Dabrafenib treatment according to genetic alterations
- Primary Outcome Measures
Name Time Method Radiological response evaluation at 16 weeks of treatment 16 weeks Standard radiological response evaluation, like RECIST criteria.
- Secondary Outcome Measures
Name Time Method Molecular analyses predicting responses 2 years Sequencing of tumor material and blood samples
Trial Locations
- Locations (1)
Oslo University Hospital
🇳🇴Oslo, Norway